TRIM17 and bladder transitional cell carcinoma: The results showed that TRIM17 was upregulated in bladder urothelial carcinoma, cholangiocarcinoma, esophageal carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, rectum adenocarcinoma, stomach adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma, but downregulated in kidney chromophobe, kidney renal clear cell carcinoma, Kidney renal papillary cell carcinoma, and Prostate adenocarcinoma.